+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Autoimmune Disease Drugs Market - Global Forecast to 2030- Product Image
Autoimmune Disease Drugs Market - Global Forecast to 2030- Product Image
Sale

Autoimmune Disease Drugs Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904622
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Autoimmune Disease Drugs Market grew from USD 116.79 billion in 2024 to USD 125.86 billion in 2025. It is expected to continue growing at a CAGR of 7.55%, reaching USD 180.81 billion by 2030.

Autoimmune diseases pose a complex challenge to global healthcare systems, demanding innovative therapeutic strategies that balance efficacy, safety, and patient quality of life. In recent years, the therapeutic landscape has shifted dramatically, driven by breakthroughs in biologics, targeted small molecules, and a deeper understanding of immune system regulation. As prevalence rates climb and healthcare providers strive to deliver personalized care, industry stakeholders are compelled to adapt swiftly to evolving treatment modalities and regulatory frameworks.

This executive summary delivers a concise overview of key developments reshaping the autoimmune disease market, from clinical research breakthroughs to policy shifts influencing drug availability. It outlines the transformative impact of U.S. tariff adjustments, provides in-depth segmentation insights, highlights regional market dynamics, and profiles major players advancing diagnostic and therapeutic innovation. Decision-makers will find actionable recommendations designed to optimize portfolio strategies, streamline supply chains, and foster collaborative research initiatives.

By synthesizing emerging trends with practical guidance, this document equips experts and business leaders with the clarity needed to navigate an increasingly competitive and regulated environment, ensuring that patients continue to benefit from cutting-edge treatments.

Transformative Shifts in Research, Regulation, and Patient Care

The past decade has witnessed transformative shifts in research methodologies, regulatory pathways, and patient engagement models within the autoimmune disease arena. Advancements in high-throughput screening and CRISPR-based assays have accelerated target identification, enabling the rapid translation of molecular discoveries into clinical candidates. Simultaneously, regulatory authorities have implemented adaptive approval frameworks and expedited review processes, lowering development timelines for life-changing therapies.

Precision medicine has emerged as a pivotal force, with companion diagnostics guiding treatment selection and monitoring therapeutic response. Digital health platforms now facilitate remote patient monitoring, enabling real-time adjustments to dosing regimens and reducing hospital visits. As a result, healthcare providers are increasingly leveraging telehealth to enhance adherence and capture longitudinal data on treatment outcomes.

Biosimilar entrants have introduced competitive pricing dynamics, driving down costs and broadening access to proven monoclonal antibody therapies. Moreover, combination regimens pairing small molecules with biologics are under investigation to improve remission rates and mitigate adverse events. These converging trends underscore the importance of agility and cross-functional collaboration across R&D, regulatory affairs, and commercial teams.

Cumulative Impact of U.S. Tariff Adjustments on Autoimmune Therapeutics

In 2025, the implementation of revised U.S. tariffs on imported active pharmaceutical ingredients and finished biologics has further complicated the supply chain for autoimmune therapeutics. Manufacturers have reported escalated procurement costs, prompting a re-evaluation of sourcing strategies and inventory management. The ripple effect has extended to contract manufacturing organizations, which face margin pressures and must negotiate new supplier agreements.

Regulatory bodies have responded by streamlining domestic production incentives and enhancing import-export transparency. Initiatives aimed at bolstering local API manufacturing capacity have emerged, supported by public-private partnerships and tax credits. As a result, several leading drug producers have announced plans to expand U.S.-based facilities, reducing dependency on overseas suppliers and fortifying resilience against future tariff volatility.

Despite short-term cost increases, the cumulative impact of these 2025 tariff measures is catalyzing a strategic shift toward supply chain diversification and vertical integration. Stakeholders are prioritizing risk mitigation protocols, real-time tracking systems, and collaborative procurement networks to sustain uninterrupted access to critical therapies.

Comprehensive Segmentation Insights Shaping Treatment Strategies

A granular examination of market segmentation reveals nuanced opportunities for targeted innovation and commercialization. By drug class, immunosuppressants-divided into calcineurin inhibitors and mTOR inhibitors-remain foundational, while interleukin inhibitors categorized as IL-1, IL-17 and IL-6 subtypes expand precision therapy options. Monoclonal antibodies, including both biosimilar and innovator molecules, continue to dominate high-value treatment protocols, alongside TNF inhibitors such as adalimumab, etanercept and infliximab. Indication-based analysis highlights distinct growth trajectories in ankylosing spondylitis across acute and chronic phases, inflammatory bowel disease splitting into Crohn’s disease and ulcerative colitis, psoriasis presenting as plaque or pustular subtypes, and rheumatoid arthritis differentiated by early-stage and advanced-stage manifestations.

Route of administration insights show a clear dichotomy: oral therapies with liquid and solid formulations cater to patient convenience, while parenteral options-both intravenous and subcutaneous-address rapid bioavailability requirements. Patient type segmentation underscores divergent needs among adult groups (18-65 years and above 65 years) and pediatric populations (adolescent and infant), necessitating tailored dosing and safety evaluations. Mechanism of action perspectives distinguish cellular inhibitors targeting B-cell and T-cell pathways from cytokine inhibitors focusing on receptor blockade and release modulation.

Further differentiation by molecule type accentuates the rise of large molecules-such as antibody-cytokine fusion proteins and recombinant proteins-alongside small molecules, notably thalidomide analogs and tyrosine kinase inhibitors. End-user segmentation delineates private and public hospital channels in parallel with online and retail pharmacies. Finally, development stage analysis spans pre-clinical research, phased clinical trials (I, II, and III), and FDA-approved therapies, split between established and recent approvals. Together, these multi-dimensional insights inform strategic prioritization across R&D pipelines, commercial launches and lifecycle management.

Key Regional Dynamics and Emerging Market Opportunities

Regional dynamics exert a powerful influence on market expansion and access pathways. In the Americas, robust reimbursement frameworks and high levels of biosimilar adoption have accelerated uptake of advanced biologics, while large patient registries enable outcome tracking and real-world evidence generation. Development of localized manufacturing hubs is also on the rise, reducing lead times and mitigating tariff pressures.

Within Europe, the Middle East and Africa, diverse regulatory landscapes demand adaptive market entry strategies. EU directives on biosimilar interchangeability and pricing negotiations contrast with emerging markets’ focus on affordability and basic access. Infrastructure gaps in certain EMEA regions present challenges but also opportunities for public-sector partnerships to strengthen diagnostic and distribution networks.

Across Asia-Pacific, government-led initiatives are driving investment in domestic biopharmaceutical capabilities, with particular emphasis on novel interleukin inhibitors and small-molecule immunomodulators. Rapid urbanization and expanding healthcare coverage foster growing demand, even as manufacturers navigate variable regulatory timelines and patent environments. Strategic collaborations with local contract development and manufacturing organizations emerge as a key enabler for market penetration.

Leading Industry Stakeholders Driving Innovation

Major industry stakeholders play instrumental roles in advancing the autoimmune therapeutics ecosystem. Abbott Laboratories, AESKU.GROUP GmbH & Co. KG, AstraZeneca PLC, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, Biogenuix Medsystems Private Limited, bioMérieux S.A. and Exagen, Inc. are actively developing cutting-edge diagnostic platforms and biomarker assays that enhance patient stratification. Concurrently, F. Hoffmann-La Roche AG, Novartis AG, Pfizer, Inc. and Sanofi S.A. continue to expand their portfolios of biologics and small molecules, often leveraging strategic collaborations to access novel mechanisms of action. Technology leaders Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC and Werfen S.A. are integrating automation and digital analytics into laboratory workflows, accelerating data processing and ensuring quality control throughout the drug development continuum.

Collectively, these organizations are investing in scalable manufacturing, exploring next-generation modalities such as bispecific antibodies and cell-based therapies, and forging alliances with academic institutions and biotech innovators. Their combined efforts are setting new benchmarks for safety, efficacy and cost efficiency in autoimmune disease management.

Actionable Recommendations for Industry Leaders

  1. Strengthen Integrated Supply Chains: Establish multi-tier procurement networks that incorporate domestic API sources, backup suppliers and real-time analytics to mitigate tariff-induced cost fluctuations and ensure uninterrupted production.
  2. Prioritize Precision Medicine Investments: Expand capabilities in companion diagnostics and biomarker validation to tailor therapies to individual patient profiles, driving improved outcomes and reinforcing payer partnerships.
  3. Enhance Biosimilar Adoption Strategies: Develop comprehensive value propositions that emphasize clinical equivalence, rapid market access and total cost of therapy savings to capture share in cost-sensitive segments.
  4. Leverage Digital Health Ecosystems: Collaborate with telehealth platforms and remote monitoring providers to gather real-world evidence, optimize dosing regimens and support patient adherence across diverse demographics.
  5. Cultivate Regional Alliances: Form joint ventures and licensing agreements in high-growth geographies to navigate complex regulatory environments, build local manufacturing capacity and expand distribution reach.
  6. Accelerate Next-Generation Modalities: Allocate R&D resources toward emerging therapeutic classes such as bispecifics, fusion proteins and cell therapies, ensuring a robust pipeline that addresses unmet needs.

Conclusion: Seizing the Next Wave of Growth

The autoimmune disease therapeutics sector stands at a critical juncture, shaped by rapid technological advances, shifting policy landscapes and evolving patient expectations. By integrating the insights presented in this summary-spanning tariff impacts, segmentation nuances, regional dynamics and stakeholder capabilities-organizations can refine their strategic roadmaps and fortify competitive positioning.

Embracing adaptive supply chain models will buffer against external shocks, while investments in precision medicine and digital health will elevate patient outcomes and payer alignment. Collaborative frameworks, both within industry and across public-private boundaries, will be essential to navigate regulatory complexity and accelerate access. Finally, a sustained focus on pipeline diversification through next-generation modalities will secure long-term leadership in a market defined by continual innovation and unmet clinical needs.

Market Segmentation & Coverage

This research report categorizes the Autoimmune Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Immunosuppressants
    • Calcineurin Inhibitors
    • mTOR Inhibitors
  • Interleukin Inhibitors
    • IL-1 Inhibitors
    • IL-17 Inhibitors
    • IL-6 Inhibitors
  • Monoclonal Antibodies
    • Biosimilars
    • Innovators
  • TNF Inhibitors
    • Adalimumab
    • Etanercept
    • Infliximab
  • Ankylosing Spondylitis
    • Acute Phase
    • Chronic Phase
  • Inflammatory Bowel Disease
    • Crohn's Disease
    • Ulcerative Colitis
  • Psoriasis
    • Plaque Psoriasis
    • Pustular Psoriasis
  • Rheumatoid Arthritis
    • Advanced Stage
    • Early Stage
  • Oral
    • Liquid Formulation
    • Solid Formulation
  • Parenteral
    • Intravenous
    • Subcutaneous
  • Adult
    • 18-65 Years
    • Above 65 Years
  • Pediatric
    • Adolescent
    • Infant
  • Cellular Inhibitors
    • B-Cell Inhibition
    • T-Cell Inhibition
  • Cytokine Inhibitors
    • Cytokine Receptor Blockade
    • Cytokine Release Modulation
  • Large Molecules
    • Antibody-Cytokine Fusion Proteins
    • Recombinant Proteins
  • Small Molecules
    • Thalidomide Analogs
    • Tyrosine Kinase Inhibitors
  • Hospitals
    • Private
    • Public
  • Pharmacies
    • Online
    • Retail
  • Clinical Trials
    • Phase I
    • Phase II
    • Phase III
  • FDA Approved
    • Established Approvals
    • Recent Approvals
  • Pre-Clinical

This research report categorizes the Autoimmune Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Autoimmune Disease Drugs Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • AESKU.GROUP GmbH & Co. KG
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • Biogenuix Medsystems Private Limited
  • bioMerieux S.A.
  • Exagen, Inc.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • Werfen S.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Autoimmune Disease Drugs Market, by Drug Class
8.1. Introduction
8.2. Immunosuppressants
8.2.1. Calcineurin Inhibitors
8.2.2. mTOR Inhibitors
8.3. Interleukin Inhibitors
8.3.1. IL-1 Inhibitors
8.3.2. IL-17 Inhibitors
8.3.3. IL-6 Inhibitors
8.4. Monoclonal Antibodies
8.4.1. Biosimilars
8.4.2. Innovators
8.5. TNF Inhibitors
8.5.1. Adalimumab
8.5.2. Etanercept
8.5.3. Infliximab
9. Autoimmune Disease Drugs Market, by Indication
9.1. Introduction
9.2. Ankylosing Spondylitis
9.2.1. Acute Phase
9.2.2. Chronic Phase
9.3. Inflammatory Bowel Disease
9.3.1. Crohn's Disease
9.3.2. Ulcerative Colitis
9.4. Psoriasis
9.4.1. Plaque Psoriasis
9.4.2. Pustular Psoriasis
9.5. Rheumatoid Arthritis
9.5.1. Advanced Stage
9.5.2. Early Stage
10. Autoimmune Disease Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Oral
10.2.1. Liquid Formulation
10.2.2. Solid Formulation
10.3. Parenteral
10.3.1. Intravenous
10.3.2. Subcutaneous
11. Autoimmune Disease Drugs Market, by Patient Type
11.1. Introduction
11.2. Adult
11.2.1. 18-65 Years
11.2.2. Above 65 Years
11.3. Pediatric
11.3.1. Adolescent
11.3.2. Infant
12. Autoimmune Disease Drugs Market, by Mechanism Of Action
12.1. Introduction
12.2. Cellular Inhibitors
12.2.1. B-Cell Inhibition
12.2.2. T-Cell Inhibition
12.3. Cytokine Inhibitors
12.3.1. Cytokine Receptor Blockade
12.3.2. Cytokine Release Modulation
13. Autoimmune Disease Drugs Market, by Molecule Type
13.1. Introduction
13.2. Large Molecules
13.2.1. Antibody-Cytokine Fusion Proteins
13.2.2. Recombinant Proteins
13.3. Small Molecules
13.3.1. Thalidomide Analogs
13.3.2. Tyrosine Kinase Inhibitors
14. Autoimmune Disease Drugs Market, by End-User
14.1. Introduction
14.2. Hospitals
14.2.1. Private
14.2.2. Public
14.3. Pharmacies
14.3.1. Online
14.3.2. Retail
15. Autoimmune Disease Drugs Market, by Development Stage
15.1. Introduction
15.2. Clinical Trials
15.2.1. Phase I
15.2.2. Phase II
15.2.3. Phase III
15.3. FDA Approved
15.3.1. Established Approvals
15.3.2. Recent Approvals
15.4. Pre-Clinical
16. Americas Autoimmune Disease Drugs Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Autoimmune Disease Drugs Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Autoimmune Disease Drugs Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Abbott Laboratories
19.3.2. AESKU.GROUP GmbH & Co. KG
19.3.3. AstraZeneca PLC
19.3.4. Beckman Coulter, Inc.
19.3.5. Bio-Rad Laboratories, Inc.
19.3.6. BioAgilytix Labs, LLC
19.3.7. Biogenuix Medsystems Private Limited
19.3.8. bioMerieux S.A.
19.3.9. Exagen, Inc.
19.3.10. F. Hoffmann-La Roche AG
19.3.11. Novartis AG
19.3.12. Pfizer, Inc.
19.3.13. Sanofi S.A.
19.3.14. Siemens Healthineers AG
19.3.15. Thermo Fisher Scientific Inc.
19.3.16. Trinity Biotech PLC
19.3.17. Werfen S.A.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. AUTOIMMUNE DISEASE DRUGS MARKET MULTI-CURRENCY
FIGURE 2. AUTOIMMUNE DISEASE DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. AUTOIMMUNE DISEASE DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 22. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. AUTOIMMUNE DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INNOVATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ACUTE PHASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CHRONIC PHASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SOLID FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY 18-65 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ABOVE 65 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CELLULAR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY B-CELL INHIBITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY T-CELL INHIBITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CELLULAR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CYTOKINE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CYTOKINE RECEPTOR BLOCKADE, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CYTOKINE RELEASE MODULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CYTOKINE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LARGE MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANTIBODY-CYTOKINE FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY THALIDOMIDE ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FDA APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ESTABLISHED APPROVALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 95. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RECENT APPROVALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 96. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FDA APPROVED, 2018-2030 (USD MILLION)
TABLE 97. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CELLULAR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CYTOKINE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 118. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 119. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 120. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 122. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 123. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 124. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 125. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FDA APPROVED, 2018-2030 (USD MILLION)
TABLE 126. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CELLULAR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CYTOKINE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FDA APPROVED, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 167. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 171. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 172. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CELLULAR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 173. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CYTOKINE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 174. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 175. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 179. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 180. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 181. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 182. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FDA APPROVED, 2018-2030 (USD MILLION)
TABLE 183. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 185. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 186. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 187. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 188. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 190. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 191. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 192. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 193. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 195. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 196. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 197. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 198. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 199. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 200. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CELLULAR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 201. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CYTOKINE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 203. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 204. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 205. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 206. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 207. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 208. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 209. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 210. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FDA APPROVED, 2018-2030 (USD MILLION)
TABLE 211. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 213. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 215. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 217. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 218. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 219. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 220. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 221. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 223. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 224. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 225. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 226. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 227. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 228. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CELLULAR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 229. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CYTOKINE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 230. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 231. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 232. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 233. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 234. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 235. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 236. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 237. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 238. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FDA APPROVED, 2018-2030 (USD MILLION)
TABLE 239. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 241. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 242. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 243. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 244. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 245. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 246. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 247. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 248. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 249. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 251. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 252. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 253. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 254. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 255. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 256. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CELLULAR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 257. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CYTOKINE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 258. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 259. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 260. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 261. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 262. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 263. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 264. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 265. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 266. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FDA APPROVED, 2018-2030 (USD MILLION)
TABLE 267. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 276. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 278. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 280. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 281. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 282. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 283. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 284. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 285. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CELLULAR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 286. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CYTOKINE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 287. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 288. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 289. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 290. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 291. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 292. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
TABLE 293. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 294. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FDA APPROVED, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 308. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 309. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 310. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 311. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 312. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 313. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 314. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CELLULAR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 315. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CYTOKINE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 316. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 317. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 318. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 319. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY EN

Companies Mentioned

  • Abbott Laboratories
  • AESKU.GROUP GmbH & Co. KG
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • Biogenuix Medsystems Private Limited
  • bioMerieux S.A.
  • Exagen, Inc.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • Werfen S.A.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Autoimmune Hemolytic Anemia Treatment Market Size, Share & Trends Analysis Report by Type, Drug Class (Corticosteroids, Immunosuppressive Agents), Route Of Administration, Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

Autoimmune Hemolytic Anemia Treatment Market Size, Share & Trends Analysis Report by Type, Drug Class (Corticosteroids, Immunosuppressive Agents), Route Of Administration, Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 120 Pages
  • Global
From
Autoimmune Disease Therapeutics Market - Global Forecast to 2030 - Product Image

Autoimmune Disease Therapeutics Market - Global Forecast to 2030

  • Report
  • 198 Pages
  • Global
From
Anti-Inflammatory Therapeutics Market by Drug Class, Indication, Application - Global Forecast 2025-2030 - Product Image

Anti-Inflammatory Therapeutics Market by Drug Class, Indication, Application - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Autoimmune Disease Therapeutics - Global Strategic Business Report - Product Image

Autoimmune Disease Therapeutics - Global Strategic Business Report

  • Report
  • 456 Pages
  • Global
From
Global Kinase Inhibitor in Autoimmune Diseases - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Global Kinase Inhibitor in Autoimmune Diseases - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From

About the Autoimmune Disease Drug Market

The Autoimmune Disease Drug market is a subset of the Immune Disorders Drugs market, which focuses on treatments for diseases caused by an overactive immune system. These drugs are used to reduce inflammation, suppress the immune system, and prevent the body from attacking its own tissues. Common autoimmune diseases include rheumatoid arthritis, psoriasis, lupus, and multiple sclerosis. Autoimmune Disease Drugs are typically divided into two categories: biologics and small molecules. Biologics are large, complex molecules derived from living organisms, while small molecules are chemically synthesized. Both types of drugs are used to treat autoimmune diseases, but biologics are more effective and have fewer side effects. The Autoimmune Disease Drug market is highly competitive, with many companies developing and marketing drugs for the treatment of autoimmune diseases. Some of the major players in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.